Stockreport

Why ImmunityBio Stock Is Down More Than 20% Today [Yahoo! Finance]

ImmunityBio, Inc.  (IBRX) 
PDF Anktiva® as a treatment for certain types of bladder cancer, as of 12:32 p.m. ET today, ImmunityBio (NASDAQ: IBRX) shares are down 22.4%. The prompt? A warning letter [Read more]